Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CVRx gets $84m cash injection for Rheos

This article was originally published in Clinica

Executive Summary

CVRx is looking to wrap up clinical studies of its Rheos hypertension control device after securing $84m in its fifth and latest round of financing. New Enterprise Associates and Johnson & Johnson Development Corp were the co-lead investors. The Minneapolis, Minnesota firm will also use the funds to complete product development and build a sales infrastructure in anticipation of a product launch. In addition, the company plans to begin clinical research in the use of Rheos for treating heart failure. The implantable device will be marketed as an alternative treatment option for patients who cannot have their hypertension controlled by drugs. Rheos works by activating the carotid baroreceptors, which play a key role in the body's natural cardiovascular regulation system.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041108

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel